GG
Graham G. Walmsley
Director
OFFICERM
内部人交易记录
高级管理人员尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the full record of transactions filed by Graham G. Walmsley, Director. Officer active across 2 companies, notably Akero Therapeutics, Inc.. Cumulatively, 21 reports have been recorded. Breakdown: 12 buys · 4 sells. Total volume traded: €76.1m. History available since 19 May 2023. The latest transaction was filed on 8 October 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Graham G. Walmsley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
93,000 股Common StockSEC:0001193125-25-312122:0
1,200,000 股Common StockSEC:0001193125-25-312122:1
9,398 股Common StockSEC:0001193125-25-312122:2
26,000 股@ US$23.021.2% 占其流量Common StockSEC:0001193125-25-237295:0
9,398 股0Common StockSEC:0000950170-25-082306:0
91,309 股@ US$44.7478.7% 占其流量Common StockSEC:0000950170-25-046271:0
200,000 股@ US$48.0021.2% 占其流量Common StockSEC:0000950170-25-016559:0
700,761 股@ US$6.7513.8% 占其流量Common StockSEC:0000935836-24-000764:0
700,761 股@ US$6.7513.7% 占其流量Common StockSEC:0000935836-24-000763:0
700,000 股@ US$14.8529.2% 占其流量Common StockSEC:0000935836-24-000744:0
700,000 股@ US$14.8529.2% 占其流量Common StockSEC:0000935836-24-000425:0
508,130 股@ US$9.8414.2% 占其流量Common StockSEC:0000935836-23-000733:0
50,000 股@ US$19.80482.1% 占其流量Common StockSEC:0000950170-23-069509:0
50,000 股@ US$16.89671.8% 占其流量Common StockSEC:0000950170-23-067951:0
50,000 股@ US$16.99461.8% 占其流量Common StockSEC:0000950170-23-067951:1
25,000 股@ US$42.0592.2% 占其流量Common StockSEC:0000950170-23-041440:0
30,000 股@ US$42.69032.7% 占其流量Common StockSEC:0000950170-23-036694:0
25,000 股@ US$43.2612.3% 占其流量Common StockSEC:0000950170-23-036694:1
400,000 股@ US$26.0023.9% 占其流量Common StockSEC:0000899243-23-015665:0
120,000 股@ US$42.0010.8% 占其流量Common StockSEC:0000950170-23-023738:1
400,000 股@ US$26.0022.5% 占其流量Common StockSEC:0000950170-23-023738:0
About Graham G. Walmsley
Graham G. Walmsley is a Director at Akero Therapeutics, Inc. and Olema Pharmaceuticals, Inc. The 21 filings in the recent sample run from 2023-05-23 to 2025-12-09, with purchases totaling EUR 47998740 and sales totaling EUR 28118691, and the modal transaction nature is Acquisition.